Jill A. Howe - 14 Nov 2022 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Role
Chief Financial Officer
Signature
/s/ Grant Harbert, as Attorney-in-Fact
Issuer symbol
LCTX
Transactions as of
14 Nov 2022
Net transactions value
$0
Form type
4
Filing time
16 Nov 2022, 15:17:31 UTC
Previous filing
17 Jun 2022
Next filing
05 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LCTX Employee Stock Option (right to buy) Award $0 +1,000,000 $0.000000 1,000,000 14 Nov 2022 Common Shares 1,000,000 $1.36 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option will vest as to one quarter of the shares subject to the option on November 14, 2023, and the balance will vest in 36 successive substantially equal installments thereafter, subject to the reporting person's continuous employment.